At this time, Lu Zhengyang introduced their technical achievements in an orderly manner: "After more than a year of research and development, this nanorobot has finally been launched. Another thing I think is worth mentioning is that in addition to being used as a killer weapon to physically kill cancer cells, these nanobots can also be used as transporters to carry therapeutic drugs. ”

"If it is used as the former, the nanorobot is not mature enough at present, and it needs to be further improved from clinical trials, but we have also purchased a set of organ simulators from Huachang Technology for trials."

Lu Zhengyang is also very honest, and he has one thing to say, instead of fooling people and talking big.

"At present, the progress of our experiments has not yet been able to destroy the specified cancer cells in the cell population, and all the cells around such nanorobots, whether good or bad, will be indiscriminately subjected to a 'suicide spiral attack'."

The people present were also quite shocked when they heard this, this nanobot is now a rhythm that distinguishes between friend and foe, whether it is normal cells or cancer cells, they will be destroyed for you.

But this characteristic has led some people to think otherwise, and there are all kinds of people at the expo site, and naturally there is no shortage of personnel from the intelligence agencies of various countries.

In this exhibition area where Lu Zhengyang is located, there are foreign intelligence officers watching as tourists, and after hearing such an explanation, the first priority that comes to his mind is biological and chemical weapons.

The properties of this nanobot are enough to kill people from a microscopic scale.

The two co-founders, Lu Zhengyang and Zhao Yu, have never thought of weaponizing the technology they researched, they have always been committed to benefiting mankind, and the company they co-founded also belongs to the medical device industry.

Different positions lead to different results, once again demonstrating that technology is a double-edged sword.

Lu Zhengyang said: "The organ simulator we purchased from Huachang Technology will arrive soon, and next, our team will conduct the next stage of microbial experimental testing to continuously improve this nanorobot, and I believe that its application will truly bring good news to mankind in the future." ”

After the words fell, they also received a warm applause.

Ding Xian didn't stay in front of the stage for too long, whispered a few words with the accompanying secretary assistant, and left the stage after about ten minutes, and met Lu Zhengyang behind the scenes of the Hongrui Medical booth.

When he arrived backstage, Ding Xiancai unexpectedly found that in addition to him, there were many peer VCs who arrived before him, smiling and nodding to each other.

But Ding Xian knew that on the surface, they nodded and smiled at each other's questions, and in their hearts, they were mostly scolding each other.

In the next half hour, Lu Zhengyang met with several major VCs who came to visit to discuss, Hongrui Medical has only been established for about three years, but it has already completed the B round of financing, and without exception it is invested by Cote d'Azur and Shengfeng Capital, and does not accept other venture capital institutions.

Because the agreement between Hongrui Medical and Cote d'Azur and Shengfeng Capital is that if the company wants to carry out external financing, Cote d'Azur and Shengfeng Capital have the priority and exclusive investment, and unless they give up the priority and exclusive investment, other VC institutions will not be able to get on Hongrui's car.

Therefore, the previous financing was paid by Luo Sheng's institution, and other VC institutions were helpless, but there was no way.

However, these VC institutions have been staring at, and in the next C round of financing, they have already received the news that Luo Sheng is going to put other VCs on the car, this is not an exception, many strategic investment departments of the Cote d'Azur and Shengfeng Capital have seen potential investment projects, and the C round has been eaten alone before, and it has been shared since the C round.

This ensures that you can eat the biggest piece of the cake, and at the same time let some people in and make a fortune together, of course, there is also the possibility that the investment will fail, so take the risk together.

However, the vast majority of investment institutions are very enthusiastic, because Luo Sheng has almost no precedent for overturning, as long as he lets go, VC will not hesitate to throw money in, because Luo Sheng is at this table, everyone is very down-to-earth, even if they can't understand the model and future of a company, but as long as Luo Sheng is in the car, VCs don't think much about it at all, and they will be done with their eyes closed, and they can basically mix a mouthful of meat with Mr. Luo.

After about an hour, Ding Xian left here, and when he came out of the backstage, he was still quite satisfied, because he also successfully got into the car.

Hongrui Medical's C round of financing was successful within this hour, and there were 6 venture capital institutions participating in this round of financing, led by Shengfeng Capital, with a total of 75 million US dollars, or about 500 million yuan.

After the C round of financing, Hongrui Medical is valued at $1.15 billion, and this valuation given by the capital market means that another unicorn-level start-up technology company has been born in the technology industry.

Once a major breakthrough is made in this nanorobot developed by Hongrui Medical, the future prospects are infinite imagination.

Although it seems that the day of success is still quite far away, the technological progress made by Lu's team is visible, which gives investors great confidence that they are willing to take greater risks and give Hongrui Medical a higher valuation, and expect it to thrive.

……

Côte d'Azur CEO's Office.

Luo Sheng stood near the window of his office and silently overlooked the expo site below, his office was located with a very good view, standing next to the floor-to-ceiling windows, the expo site had an unobstructed view.

Today is the second day of the exhibition, and it is crowded and bustling.

At this time, there was a few knocks on the office door.

"Come in."

Luo Sheng turned around and looked around, and it was Yao Jianhong who walked in.

"The leadership of the Securities and Futures Commission is gone?" Luo Sheng came over from the floor-to-ceiling window and sat down on the sofa in the lounge area of the office.

Yao Jianhong, who was sitting opposite him, nodded: "Well, let's go, it's basically negotiated." ”

The leaders of the China Securities Regulatory Commission came to the Cote d'Azur in person this time for a very important event for Big A next year - the opening of the Science and Technology Innovation Board.

The Science and Technology Innovation Board is a new board that is independent of the existing main board market of Big A, and a pilot registration system will be carried out in this board.

There is no doubt that this is a very important new sector, the state attaches great importance to it, and its market positioning is the strategy of innovation-driven and scientific and technological power.

If the Science and Technology Innovation Board is to be opened, it will definitely need a number of high-quality innovative enterprises to land on the Science and Technology Innovation Board, and the new start-ups that can be called on the board are basically the Cote d'Azur.

It's really a big deal.

If there are no technology companies listed on the Cote d'Azur, the STAR Market will not be representative.

In fact, the China Securities Regulatory Commission has repeatedly studied the possibility of whether the Cote d'Azur company can be listed on the Science and Technology Innovation Board, and after the study, it directly chose to give up.

First, whether the Cote d'Azur is listed or not, you have to lobby Luo Sheng, and the China Securities Regulatory Commission also knows that Luo Sheng will not let the company go public, including Huawei, because there is really no shortage of money at all, and there is no need for margin financing and securities lending.

Another reason that cannot be ignored is just as important, with the current size of the Cote d'Azur, if it is open on the Science and Technology Innovation Board, it will be really amazing.

If the Cote d'Azur is listed, there is no need to think that its valuation must start at 20 trillion yuan, and it will start at 3 trillion US dollars regardless of exchange rate changes.

The blood of the entire big A stock market has to be drained by this company, and it may not be able to slow down in two or three years, so the China Securities Regulatory Commission gave up.

The big A motherboard already has the super giant of Azure pure electric car company, with a current market value of 11.47 trillion.

The conclusion is that the current big A is not enough to carry two super giants at the same time.

However, the opening of the science and technology innovation board has already set the tone, but the outside world does not know about this matter, and the specific opening time has not yet been announced, and only a very few institutions have been notified, and the Cote d'Azur is one of them.

Obviously, the opening of the science and technology innovation board cannot be without high-quality stocks, and it must be opened beautifully.

"The first batch of listed companies on the Science and Technology Innovation Board is set at 28, and the China Securities Regulatory Commission hopes that we can provide 10 high-quality stocks as weighted stocks to open on the Science and Technology Innovation Board. This is a batch of 35 companies selected by me from the major subsidiaries and holding companies of the Côte d'Azur. ”

Yao Jianhong put the documents he brought on the table and pushed them in front of Luo Sheng, who opened the list on the list.

Lao Yao has selected 35 companies, but the 10 companies that have finally been determined to land on the Science and Technology Innovation Board are handed over to Luo Sheng to make a decision.

The first is Xiongxin Electronics, the largest chip foundry in China, and the highest valuation among the first batch of 28 listed companies on the Science and Technology Innovation Board, with a valuation of 1.45 trillion yuan, or about $215 billion excluding exchange rate changes, which is less than $20 billion from the current market value of the performance leader.

Once Xiongxin Electronics is on the Science and Technology Innovation Board, there is no suspense that it will become the absolute leading stock, far ahead of other listed companies in the Science and Technology Innovation Board.

Even if it is placed in the entire big A, its market value ranking is also ranked fifth, and the newly opened science and technology innovation board does need such a needle and a proper card.

Xiongxin Electronics...... Well. ”

Luo Sheng looked at it for a while, and then took out a pen and ticked it on the company's directory, which means that he agreed to Xiongxin Electronics to open on the Science and Technology Innovation Board, and there is no doubt that it is the first stock of the board.

The second is Jingchuang Technology, the most promising start-up company for EDA software development in China, with a valuation of 57 billion yuan.

The third is engaged in the field of medical devices, Huachang Technology, which focuses on the development of organ simulators founded by Cao Junhui, has achieved profitability and has business dealings with major biomedical R&D giants around the world, with a valuation of 320 billion yuan.

The fourth company is Borche Technology, which develops human bionic prosthetics, and the company founded by Chen Xin after the 90s has also achieved profitability, with a valuation of 178 billion yuan.

"Just these 10 companies, take them and report them to the Securities Regulatory Commission."

About ten minutes later, Luo Sheng selected 10 of the 35 companies selected by Lao Yao to land on the Science and Technology Innovation Board and returned the documents to him.

"Okay, I'll take care of it." Yao Jianhong took back the documents and left Luo Sheng's office.

There is no doubt that these 10 companies that are about to land on the Science and Technology Innovation Board are the best targets for value investment, and they are definitely the most favored stocks for price investment.

The industry in which these 10 companies are located is the chip semiconductor and medical device industry, and it can be met that the trend of the technology and medical industry in 2019 next year will definitely usher in a plate bull market.

……